Request Demo
Recent blog posts
Latest Hotspot
8 min read
NCOA1 Biologics Sequence Review Report 2026: Nuclear receptor coactivator 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NCOA1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NCAM2 Biologics Sequence Review Report 2026: Neural cell adhesion molecule 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NCAM2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MYDGF Biologics Sequence Review Report 2026: Myeloid-derived growth factor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MYDGF sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MST1 Biologics Sequence Review Report 2026: Hepatocyte growth factor-like protein Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MST1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MRGPRD Biologics Sequence Review Report 2026: Mas-related G protein-coupled receptor member D Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MRGPRD sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MNDA Biologics Sequence Review Report 2026: Myeloid cell nuclear differentiation antigen Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MNDA sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MLANA Biologics Sequence Review Report 2026: Melanoma antigen recognized by T-cells 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MLANA sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MEGF9 Biologics Sequence Review Report 2026: Multiple epidermal growth factor-like domains protein 9 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MEGF9 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MEGF6 Biologics Sequence Review Report 2026: Multiple epidermal growth factor-like domains protein 6 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MEGF6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MEGF10 Biologics Sequence Review Report 2026: Multiple epidermal growth factor-like domains protein 10 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MEGF10 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MCHR2 Biologics Sequence Review Report 2026: Melanin-concentrating hormone receptor 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MCHR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MCHR1 Biologics Sequence Review Report 2026: Melanin-concentrating hormone receptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MCHR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.